Introduction
Hypercalcemia is one of the most frequent electrolyte disorders in
patients with malignant diseases [1], presenting in about one
quarter of these patients [2]. Hypercalcemia could result from
osteolytic lesions or from production of humoral substances like
parathyroid hormone-related protein (PTHrP) or uncontrolled synthesis
and secretion of 1-25(OH)2D3 by the tumoral cell or
macrophages. Within tumor-related etiologies, multiple myeloma, breast,
lung, and kidney cancers are the most frequent [3,4]. In these
diseases, hypercalcemia has been reported in 30% and 60% of patients
with multiple myeloma and T-cell non-Hodgkin lymphoma [1].However, hypercalcemia has only been reported in 7-8% of patients with
B-cell non-Hodgkin lymphoma (NHL) and its prevalence and its prognostic
value is unclear [2].